Colorectal cancer in review: the role of the EGFR pathway

Bibliography

• Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003;30:3-11
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 2001;19:32S-40S
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-611
   PubMed Web of Science ®Google Scholar
• Stein RA, Staros JV. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol 2006;6:79
   PubMed Web of Science ®Google Scholar
• Kraus MH, Issing W, Miki T, Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86:9193-7
   PubMed Web of Science ®Google Scholar
• Plowman GD, Culouscou JM, Whitney GS, Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993;90:1746-50
   PubMed Web of Science ®Google Scholar
• Sithanandam G, Anderson LM. The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 2008;15(1):413-48
   PubMed Web of Science ®Google Scholar
• Sweeney C, Fambrough D, Huard C, Growth factor-specific signaling pathway stimulation and gene expression mediated by ErbB receptors. J Biol Chem 2001;276:22685-98
   PubMed Web of Science ®Google Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232
   PubMed Web of Science ®Google Scholar
• Pai R, Soreghan B, Szabo IL, Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8(3):289-93
   PubMed Web of Science ®Google Scholar
• Cohen G, Mustafi R, Chumsangsri A, Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res 2006;66:5656-64
   PubMed Web of Science ®Google Scholar
• Radinsky R, Risin S, Fan D, Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1995;1:19-31
   PubMed Web of Science ®Google Scholar
• Hemming AW, Davis NL, Kluftinger A, Prognostic markers of colorectal cancer: an evaluation of DNA content, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992;51:147-52
   PubMed Web of Science ®Google Scholar
• Mayer A, Takimoto M, Fritz E, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-60
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-46
   PubMed Web of Science ®Google Scholar
• Khorana AA, Ryan CK, Cox C, Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 2003;97:960-8
   PubMedGoogle Scholar
• Kapitanovic S, Radosevic S, Kapitanovic M, The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 1997;112:1103-13
   PubMed Web of Science ®Google Scholar
• Half E, Broaddus R, Danenberg KD, HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 2004;108:540-8
   PubMed Web of Science ®Google Scholar
• Sauer T, Guren MG, Noren T, Dueland S. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy? Histopathology 2005;47:560-4
   PubMed Web of Science ®Google Scholar
• Yasui W, Sumiyoshi H, Hata J, Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 1988;48:137-41
   PubMed Web of Science ®Google Scholar
• Kapitanovic S, Radosevic S, Slade N, Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 2000;126:205-11
   PubMed Web of Science ®Google Scholar
• Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065-71
   PubMed Web of Science ®Google Scholar
• Kountourakis P, Pavlakis K, Psyrri A, Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 2006;6:46
   PubMed Web of Science ®Google Scholar
• Uner A, Ebinc FA, Akyurek N, Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol 2005;27:225-8
   PubMed Web of Science ®Google Scholar
• Venkateswarlu S, Dawson DM, St Clair P, Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells. Oncogene 2002;21:78-86
   PubMed Web of Science ®Google Scholar
• Vadlamudi R, Mandal M, Adam L, Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-14
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Haley JD, Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity. Mol Cancer Ther 2006;5:2051-9
   PubMed Web of Science ®Google Scholar
• Derks S, Postma C, Carvalho B, Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 2008;29:434-9
   PubMed Web of Science ®Google Scholar
• Prenzel N, Zwick E, Daub H, EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999;402:884-8
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998;4:13-20
   PubMed Web of Science ®Google Scholar
• Rubin Grandis J, Melhem MF, Gooding WE, Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32
   PubMed Web of Science ®Google Scholar
• Shia J, Klimstra DS, Li AR, Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 2005;18:1350-6
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer. Curr Opin Oncol 2005;17:118-22
   PubMed Web of Science ®Google Scholar
• Moroni M, Veronese S, Benvenuti S, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005;6:279-86
   PubMed Web of Science ®Google Scholar
• Ooi A, Takehana T, Li X, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol 2004;17:895-904
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Hunter-Schaedle K, Shannon KM. Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest 2006;116:847-52
   PubMed Web of Science ®Google Scholar
• Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-13S
   PubMed Web of Science ®Google Scholar
• Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50
   PubMed Web of Science ®Google Scholar
• Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004;5:292-302
   PubMed Web of Science ®Google Scholar
• Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001;1:118-29
   PubMed Web of Science ®Google Scholar
• Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. Curr Opin Biotechnol 2002;13:609-14
   PubMed Web of Science ®Google Scholar
• Burton DR, Woof JM. Human antibody effector function. Adv Immunol 1992;51:1-84
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006;33:369-85
   PubMed Web of Science ®Google Scholar
• Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs 2005;23:391-409
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Hwang JJ, Zamboni WC, Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004;22:858-65
   PubMed Web of Science ®Google Scholar
• Goldstein NI, Prewett M, Zuklys K, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-8
   PubMed Web of Science ®Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr, Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
   PubMed Web of Science ®Google Scholar
• Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59:1935-40
   PubMed Web of Science ®Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74
   PubMed Web of Science ®Google Scholar
• Wu X, Fan Z, Masui H, Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 1995;95:1897-905
   PubMed Web of Science ®Google Scholar
• Wu X, Rubin M, Fan Z, Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene 1996;12:1397-403
   PubMed Web of Science ®Google Scholar
• Liu B, Fang M, Schmidt M, Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000;82:1991-9
   PubMed Web of Science ®Google Scholar
• Naramura M, Gillies SD, Mendelsohn J, Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993;37:343-9
   PubMed Web of Science ®Google Scholar
• Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13
   PubMed Web of Science ®Google Scholar
• Sunada H, Yu P, Peacock JS, Mendelsohn J. Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol 1990;142:284-92
   PubMed Web of Science ®Google Scholar
• Patel D, Lahiji A, Patel S, Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res 2007;27:3355-66
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Cetuximab monotherapy and cetuximabplus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345
   PubMed Web of Science ®Google Scholar
• Wilke H, Glynne-Jones R, Thaler J, Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study. J Clin Oncol 2008;26(33):5335-43
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Maurel J, Fehrenbacher L, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008;26(14):2311-9
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nowacki M, Lang I, Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18 Suppl):4000
   Google Scholar
• Schuch G, Staroslawska E, Nowacki M, Cetuximab plus 5-FU/FA/ oxaliplatin (FOLFOX-4) in the first-line treatment of mCRC: OPUS, a phase II study [abstract O-0022]. Ann Oncol 2007;18(Suppl 7):vii18
   Google Scholar
• Gibson TB, Ranganathan A, Grothey A, Randomized Phase III trial results ofanitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody,in metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:29-31
   PubMed Web of Science ®Google Scholar
• Hecht JR, Mitchell E, Chidiac T, An update analysis of safety and efficacy of oxaliplatin (Ox)/bevacizumab (bev) ± panitumumab (pmab) for fist-line treatment (tx) of metastatic colorectal cancer (mCRC) from a randomized, controlled trial (PACCE). Presented at: the American Society of Clinical Oncology: 2008 Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 273
   Google Scholar
• International Society of Gastrointestinal Oncology annual meeting: Abstract 0926. Presented October 3, 2009
   Google Scholar
• International Society of Gastrointestinal Oncology annual meeting: Abstract 0925. Presented October 3, 2009
   Google Scholar
• Vanhoefer U, Tewes M, Rojo F, Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004;22:175-84
   PubMed Web of Science ®Google Scholar
• Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2007;29:697-735
   PubMedGoogle Scholar
• Kuo T, Cho CD, Halsey J, Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J Clin Oncol 2005;23:5613-9
   PubMed Web of Science ®Google Scholar
• Cho CD, Fisher GA, Halsey J, Sikic BI. Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies. Invest New Drugs 2006;24:117-23
   PubMed Web of Science ®Google Scholar
• Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 1994;269:27595-602
   PubMed Web of Science ®Google Scholar
• Prewett M, Rockwell P, Rockwell RF, The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 1996;19:419-27
   PubMed Web of Science ®Google Scholar
• Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003;284:122-30
   PubMed Web of Science ®Google Scholar
• Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc) 2003;39(Suppl C):1-16
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B, Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005;280:31182-9
   PubMed Web of Science ®Google Scholar
• Burgess AW, Cho HS, Eigenbrot C, An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003;12:541-52
   Google Scholar
• Cho HS, Mason K, Ramyar KX, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60
   PubMed Web of Science ®Google Scholar
• Garrett TP, McKern NM, Lou M, The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003;11:495-505
   PubMed Web of Science ®Google Scholar
• Adams CW, Allison DE, Flagella K, Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006;55:717-27
   PubMed Web of Science ®Google Scholar
• Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Graus-Porta D, Beerli RR, ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 1998;18:5042-51
   PubMed Web of Science ®Google Scholar
• Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-31
   PubMed Web of Science ®Google Scholar
• Yen L, Benlimame N, Nie ZR, Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol Biol Cell 2002;13:4029-44
   PubMed Web of Science ®Google Scholar
• Baselga J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2002;2:93-5
   PubMed Web of Science ®Google Scholar
• Fendly BM, Winget M, Hudziak RM, Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 1990;50:1550-8
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004;5:317-28
   PubMed Web of Science ®Google Scholar
• Agus DB, Gordon MS, Taylor C, Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005;23:2534-43
   PubMed Web of Science ®Google Scholar
• Saltz LB, Lenz H, Hochster H, Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25(29):4557-61
   PubMed Web of Science ®Google Scholar
• Punt CJ, Tol J, Rodenburg CJ, Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 2008;26(20 Suppl):, abstract LBA4011
   Google Scholar
• Baselga J, Schöffski P, Rojo F, A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC) [abstract 3006]. J Clin Oncol 2006;24(18 Suppl):122s
   Web of Science ®Google Scholar
• Tournigand C, Lledo G, Delord J, Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR). ASCO Annual Meeting Proceedings Part I. J Clin Oncol, 2007; 25(18 Suppl ):4097
   Web of Science ®Google Scholar
• Tejpar S, Peeters M, Humblet H, Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. J Clin Oncol (Meeting Abstract) 2007;25:4037
   Web of Science ®Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235-46
   PubMed Web of Science ®Google Scholar
• Chung KY, Shia J, Kemeny NE, Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bearzi I, Berardi R, Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8
   PubMed Web of Science ®Google Scholar
• Atkins D, Reiffen KA, Tegtmeier CL, Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901
   PubMed Web of Science ®Google Scholar
• Defize LH, Boonstra J, Meisenhelder J, Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors. J Cell Biol 1989;109:2495-507
   PubMed Web of Science ®Google Scholar
• King AC, Cuatrecasas P. Resolution of high and low affinity epidermal growth factor receptors. Inhibition of high affinity component by low temperature, cycloheximide, and phorbol esters. J Biol Chem 1982;257:3053-60
   PubMed Web of Science ®Google Scholar
• Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009;7(1):45-53, 64
   PubMedGoogle Scholar
• Burmer GC, Loeb LA. Mutations in the KRAS2 oncogene during progressive stages of human colon carcinoma. Proc Natl Acad Sci USA 1989;86(7):2403-7
   PubMed Web of Science ®Google Scholar
• Tejpar S, Peeters M, Humblet Y, Relationship of efficacy with K-RAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol (ASCO Annual Meeting Abstracts) 2008;26:4001
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lang I, D'haens G, K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol (ASCO Annual Meeting Abstracts) 2008;26:2
   Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, Wild-type K-RAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Yi J, Ince W, The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;14(1):22-8
   PubMed Web of Science ®Google Scholar
• Lenz H, Zhang W, Yang D, Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Gastrointestin Cancers Symp 2007;401: abstract
   Google Scholar
• Nagashima F, Zhang W, Gordon M, EGFR, Cox-2, and EGF polymorphisms associated with progression-free survival of EGFR-expressing metastatic colorectal cancer patients treated with single-agent cetuximab (IMCL-0144). J Clin Oncol (Meeting Abstracts) 2007;25:4129
   Web of Science ®Google Scholar
• Saif MW, Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009;7(1):45-53, 64
   PubMedGoogle Scholar
• Finocchiaro G, Cappuzzo F, Janne PA, EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer. J Clin Oncol(Meeting Abstracts) 2007;25:4021
   Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
   PubMed Web of Science ®Google Scholar